Compare IH & RCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IH | RCEL |
|---|---|---|
| Founded | 1996 | N/A |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Medical/Dental Instruments |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 142.2M | 114.3M |
| IPO Year | 2020 | N/A |
| Metric | IH | RCEL |
|---|---|---|
| Price | $2.59 | $3.50 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $11.75 |
| AVG Volume (30 Days) | 12.3K | ★ 204.3K |
| Earning Date | 12-26-2025 | 11-06-2025 |
| Dividend Yield | ★ 3.37% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.29 | N/A |
| Revenue | ★ $123,215,612.00 | $72,401,000.00 |
| Revenue This Year | $39.02 | $13.12 |
| Revenue Next Year | N/A | $27.56 |
| P/E Ratio | $8.81 | ★ N/A |
| Revenue Growth | N/A | ★ 20.59 |
| 52 Week Low | $1.55 | $3.35 |
| 52 Week High | $3.60 | $14.16 |
| Indicator | IH | RCEL |
|---|---|---|
| Relative Strength Index (RSI) | 37.24 | 36.87 |
| Support Level | $2.66 | $3.42 |
| Resistance Level | $2.89 | $3.93 |
| Average True Range (ATR) | 0.16 | 0.21 |
| MACD | -0.03 | 0.00 |
| Stochastic Oscillator | 0.00 | 11.94 |
iHuman Inc is a Chinese company that uses artificial intelligence to create technology-driven puzzle products for children, making parenting easier and children happier. The company offers a range of intellectual development products that are designed to make the child-rearing experience more manageable for parents while turning intellectual development into a fun journey for children. Its revenue is generated from subscription fees paid by users for premium content on their self-directed and interactive online applications, as well as offline products and other sources.
Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently in rollout across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.